Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 6, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,219 pence per share; lowest price paid was 1,211 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.71% of total issued share capital and 9.54% of total voting rights).
- Shares in Issue: 5,170,133,472 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 800,000 repurchased shares. Consequently, the Company's Treasury shareholding increased to 493,224,284 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,170,133,472) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.54%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.